| Jessica Lauren Sommer, DO | |
|
1625 N George Mason Dr Ste 325, Arlington, VA 22205-3690 | |
| (703) 717-4600 | |
| (703) 717-4601 |
| Full Name | Jessica Lauren Sommer |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 12 Years |
| Location | 1625 N George Mason Dr Ste 325, Arlington, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861759227 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 0102204588 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Virginia Hospital Center | Arlington, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Virginia Hospital Center Physician Group Llc | 8426231119 | 241 |
News Archive
Today, around the world, more than two billion world citizens do not have access to emergency and essential surgical care. The results are devastating, leading to more than 500,000 maternal deaths and more than 5 million fatalities associated with everyday injuries such as road traffic accidents and burns. This lack of surgical care is arguably a top killer around the world but mostly ignored by organizations that can affect positive change.
Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, president and CEO, presented at the invitation-only World Knowledge Forum being held in Seoul, South Korea.
FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.
CytRx Corporation, a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that it has been granted a key patent by the European Patent Office that covers through 2024 the use of its orally available molecular chaperone amplifier drug candidate arimoclomol for the treatment or prevention of neurodegenerative diseases of the central nervous system (CNS).
› Verified 7 days ago
| Entity Name | Privia Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013042480 PECOS PAC ID: 4385682061 Enrollment ID: O20050422000298 |
News Archive
Today, around the world, more than two billion world citizens do not have access to emergency and essential surgical care. The results are devastating, leading to more than 500,000 maternal deaths and more than 5 million fatalities associated with everyday injuries such as road traffic accidents and burns. This lack of surgical care is arguably a top killer around the world but mostly ignored by organizations that can affect positive change.
Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, president and CEO, presented at the invitation-only World Knowledge Forum being held in Seoul, South Korea.
FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.
CytRx Corporation, a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that it has been granted a key patent by the European Patent Office that covers through 2024 the use of its orally available molecular chaperone amplifier drug candidate arimoclomol for the treatment or prevention of neurodegenerative diseases of the central nervous system (CNS).
› Verified 7 days ago
| Entity Name | Virginia Hospital Center Physician Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144415480 PECOS PAC ID: 8426231119 Enrollment ID: O20110317000305 |
News Archive
Today, around the world, more than two billion world citizens do not have access to emergency and essential surgical care. The results are devastating, leading to more than 500,000 maternal deaths and more than 5 million fatalities associated with everyday injuries such as road traffic accidents and burns. This lack of surgical care is arguably a top killer around the world but mostly ignored by organizations that can affect positive change.
Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, president and CEO, presented at the invitation-only World Knowledge Forum being held in Seoul, South Korea.
FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.
CytRx Corporation, a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that it has been granted a key patent by the European Patent Office that covers through 2024 the use of its orally available molecular chaperone amplifier drug candidate arimoclomol for the treatment or prevention of neurodegenerative diseases of the central nervous system (CNS).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jessica Lauren Sommer, DO 4550 Strutfield Ln Apt 2414, Alexandria, VA 22311-4977 Ph: (518) 528-4937 | Jessica Lauren Sommer, DO 1625 N George Mason Dr Ste 325, Arlington, VA 22205-3690 Ph: (703) 717-4600 |
News Archive
Today, around the world, more than two billion world citizens do not have access to emergency and essential surgical care. The results are devastating, leading to more than 500,000 maternal deaths and more than 5 million fatalities associated with everyday injuries such as road traffic accidents and burns. This lack of surgical care is arguably a top killer around the world but mostly ignored by organizations that can affect positive change.
Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, president and CEO, presented at the invitation-only World Knowledge Forum being held in Seoul, South Korea.
FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.
CytRx Corporation, a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that it has been granted a key patent by the European Patent Office that covers through 2024 the use of its orally available molecular chaperone amplifier drug candidate arimoclomol for the treatment or prevention of neurodegenerative diseases of the central nervous system (CNS).
› Verified 7 days ago
Dr. Luis E. Sanz, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1625 N George Mason Dr, Suite 475, Arlington, VA 22205 Phone: 703-717-4000 Fax: 703-717-4009 | |
Amanda Elaine Rohn, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1625 N George Mason Dr, Suite 325, Arlington, VA 22205 Phone: 703-717-4600 | |
Saliatou Maikarfi Jordan, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4040 Fairfax Dr Ste 801, Arlington, VA 22203 Phone: 571-970-6050 Fax: 571-950-6352 | |
Dr. Jennifer Lynn Kilmer, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1625 N George Mason Dr, Suite 465, Arlington, VA 22205 Phone: 703-717-4050 Fax: 703-717-4057 | |
Jessica Leigh Hardesty, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1701 N George Mason Dr, Arlington, VA 22205 Phone: 703-717-4502 | |
Melanie Polin, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1701 N George Mason Dr, Arlington, VA 22205 Phone: 703-717-4600 | |
Dr. William Albright Burch Iii, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 5275 Lee Highway, Suite 101, Arlington, VA 22207 Phone: 703-358-8700 Fax: 703-358-8703 |